Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety of inhaled sodium nitrite in adults with Cystic Fibrosis
and chronic Pseudomonas infections, and determine the ability of sodium nitrite to reduce the
burden of Pseudomonas.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Schmidhofer, Mark, MD University of Pittsburgh
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics Mast Therapeutics, Inc.